Protalix BioTherapeutics, Inc. Share Price
PLXProtalix BioTherapeutics, Inc. Stock Performance
Open $2.20 | Prev. Close $2.21 | Circuit Range N/A |
Day Range $2.13 - $2.24 | Year Range $1.32 - $3.19 | Volume 47,447 |
Average Traded $2.17 |
Protalix BioTherapeutics, Inc. Share Price Chart
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Protalix BioTherapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
19-Mar-26 | $2.20 | $2.23 | +0.00% |
19-Mar-26 | $2.20 | $2.23 | +0.45% |
18-Mar-26 | $2.25 | $2.21 | -20.75% |
17-Mar-26 | $2.86 | $2.79 | -2.95% |
16-Mar-26 | $2.87 | $2.88 | +1.77% |
13-Mar-26 | $2.83 | $2.83 | +1.07% |
12-Mar-26 | $2.83 | $2.80 | -3.11% |